GlobeNewswire Inc | Dec 11, 2020 06:57PM EST

December 11, 2020

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (Ziopharm or the Company), today issued a statement in connection with the consent solicitation (the Consent Solicitation) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, WaterMill) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Companys GREEN Consent Revocation Card.

The statement is as follows:

We have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it does not appear to have the level of shareholder support for its proposals it claimed to have. As has been the case since this process commenced in mid-October, Ziopharms Board and management team remain fully committed to acting in the best interest of shareholders and have relayed the Companys willingness to reach an amicable resolution with WaterMill. It is our preference to resolve this matter amicably so we can continue to focus on our important progress toward developing therapies that could treat the millions of people globally diagnosed with a solid tumor each year.

Information related to the Consent Solicitation can be found at www.ZiopharmForward.com.

About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as anticipate, believe, contemplate, continue, could, estimate, expect, hope, intend, may, might, objective, ongoing, plan, potential, predict, project, should, target, will, or would or similar expressions and the negatives of those terms. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other activities by WaterMill and/or other investors, the risks and uncertainties disclosed in Ziopharms most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the Securities and Exchange Commission (the SEC). All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.

Important Additional Information and Where to Find ItZiopharm has filed a definitive consent revocation statement (the Consent Revocation Statement) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SECs website ( http://www.sec.gov) or from Ziopharms website (www.ziopharm.com) by clicking on Investors and then SEC Filings.

Investor Relations Contacts:Adam D. Levy, PhD, MBAEVP, Investor Relations and Corporate Communications(508) 552-9255alevy@ziopharm.com

Michael VerrechiaMorrow Sodali(212) 300-2476m.verrechia@morrowsodali.com

Media Relations Contacts:Chris Kittredge, Andrew Cole and Zachary TramontiSard Verbinnen & Co.Ziopharm-SVC@sardverb.com